Latest Conference Articles

Expert Advises on Managing Side Effects of Targeted Lung Cancer Therapies

Jyoti D. Patel, MD, provides insight into managing the toxicities associated with molecular therapies used to treat patients with lung cancers.

Dr. Bible Discusses the Promise of Pemetrexed in Follicular Thyroid Cancers

Keith C. Bible, MD, PhD, professor of oncology, Mayo Clinic, discusses the promise of pemetrexed and carboplatin as a potential treatment option for patients with follicular cell-derived thyroid cancers.

ATA Highlights New Thyroid Cancer Research

The impact of RAI on long-term outcomes, potential combination strategies, molecular profiling, and novel therapeutics for patients with thyroid cancer were among some of the topics highlighted at the 2014 ATA Annual Meeting.

Dr. Busaidy on the Association Between THST and Improved Outcomes

Naifa L. Busaidy, MD, associate professor, MD Anderson Cancer Center, discusses the results of a cooperative study that investigated the association between long-term thyroid hormone suppression therapy and improved outcomes in patients.

Phase II Study Shows Promising Efficacy for Nivolumab in Advanced NSCLC

The PD-1 immune checkpoint inhibitor nivolumab achieved an ORR of 15% with a median duration of response that was not yet reached at a median 11-month follow-up for patients with advanced, refractory NSCLC.

Moderate THST Improves Outcomes in Differentiated Thyroid Cancer

Long-term moderate thyroid hormone suppression therapy is associated with improved outcomes in patients with differentiated thyroid cancer.

Dr. Nucera Discusses the Role of RNA in Thyroid Cancer

Carmelo Nucera, MD, PhD, endocrinologist, assistant professor, Harvard Medical School, Division of Experimental Pathology, Beth Israel Deaconesss Medical Center, Boston, discusses the role of RNA in thyroid cancer

Disease-Related Variables Predictive of Outcomes With Sorafenib in DTC

Numerous disease-related variables could serve as prognostic and predictive factors for treatment outcomes with sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer.

Afatinib Extends OS by Approximately 1 Year in Subgroup of NSCLC

First-line afatinib (Gilotrif) improved overall survival (OS) by about 1 year in patients with advanced non–small cell lung cancer (NSCLC) whose tumors harbor EGFR exon 19 deletions according to results from the LUX-Lung 3 and the LUX-Lung 6 phase III randomized trials.

Dr. Dadu on Reducing MTC-Related Diarrhea With CASAD

Ramona Dadu, MD, from the MD Anderson Cancer Center, discusses the results of a pilot study that examined the efficacy of CASAD, a natural clay, to reduce medullary thyroid cancer-related diarrhea.

Dr. Govindan on the Potential for Alectinib

Ramaswamy Govindan, MD, Director, Thoracic Oncology, Co-Director, Section of Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses the potential for the ALK inhibitor alectinib.

PD-1 Immunotherapies Induce Painless Thyroiditis in Patients With Metastatic Malignancies

Treatment with PD-1 immunotherapy across various oncology clinical trials has been associated with the induction of painless thyroiditis, characterized by transient thyrotoxicosis and hypothyroidism, in patients with metastatic malignancies

Post-Operative Radiation Therapy Improves Overall Survival in NSCLC Patients

Patients with NSCLC who received postoperative radiation therapy lived 4 months longer on average than patients who did not receive radiation but who had the same disease site, tumor histology, and treatment criteria, according to a large retrospective study.

Dr. Camidge on Inhibiting Initial Activating EGFR Mutations and the T790M Resistance Mutation

D. Ross Camidge, MD, PhD, discusses CO-1686 (rociletinib) and AZD9291, two agents that inhibit initial activating EGFR mutations and the T790M resistance mutation.

Dr. Cohen Discusses the Challenges of Treating Medullary Thyroid Cancer

Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses the challenges of treating Medullary Thyroid Cancer (MTC).

Molecular Profiling Reveals Potential Targets in SCLC, Lung NETs

Molecular profiling has revealed several tumor markers that could be utilized as therapeutic targets for patients with small cell lung cancer (SCLC) or lung neuroendocrine tumors (NETs).

PCP Knowledge Gap Could Affect Lung Cancer Screening Implementation

A new study suggests a knowledge gap in Primary Care Providers' familiarity with screening guidelines could also be a barrier to successful implementation.

Dr. Sequist Discusses the OS Analysis of LUX-Lung 3 and LUX-Lung 6

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses the overall survival analysis of the LUX-Lung 3 and LUX-Lung 6 trials.

Reducing Lung Biopsies May Cut Costs, Improve Patient Outcomes

Biopsies were found to be the most costly tool used in lung cancer diagnosis, and may be performed too frequently based on negative test results and adverse events.

Dr. Gandara Discusses the Future of Clinical Trial Designs

David R. Gandara, MD, from UC Davis Comprehensive Cancer Center, discusses the future of clinical trial designs.

Molecular Diagnostics Focus on Thyroid Nodule Classification

New data being presented at the 84th Annual Meeting of the American Thyroid Association show promise for two molecular tests that help identify indeterminate thyroid nodules as either benign or malignant.

Dr. Metz Discusses Using a Multidisciplinary Approach When Treating NETs

David C. Metz, MBBCh, professor of medicine, co-director, GI Physiology laboratory, Hospital of the University of Pennsylvania, discusses using a multidisciplinary approach to treating neuroendocrine tumors (NETs).

Somatic Mutations in the ATRX Gene Reported for the First Time in Pheochromocytomas/ Paragangliomas

Somatic mutations in the ATRX gene are observed in about 13% of pheochromocytomas/paragangliomas, the first such report of somatic ATRX mutations in these tumors.

Dr. Kulke on Unanswered Questions Surrounding the Treatment of NETs

Matthew Kulke, MD, comments on some unanswered questions surrounding the treatment of neuroendocrine tumors (NETs).

CDKN1B Mutation May Be Linked to Worse Survival in GEP NETs

Low nuclear expression of CDKN1B, a cyclin-dependent kinase inhibitor gene that encodes p27, in gastroenteropancreatic (GEP) neuroendocrine tumors (NETs) appears to be associated with a worse prognosis.

Few Agents Better Than Somatostatin Analogs for Symptom Control in Carcinoid Syndrome

Somatostatin analogs remain the mainstay of medical therapy for symptom control in patients with carcinoid syndrome.

Subcutaneous Octreotide May Offer Better Option for Managing NETS Symptoms

A subcutaneous depot formulation of octreotide has a rapid onset, greater bioavailability, and a similar duration of effect compared with intramuscular octreotide long-acting repeatable.

Axitinib Shows Promise in Carcinoid Tumors

The rate of PFS with axitinib in patients with advanced carcinoid tumors is promising.

Everolimus Improves Outcomes in Pancreatic Neuroendocrine Tumors

Treatment with the mTOR inhibitor everolimus improved overall survival by 6.34 months over placebo for patients with pancreatic neuroendocrine tumors.

Dr. Reidy-Lagunes on Determining the Site of Unknown Primary in Metastatic NETs

Diane Reidy-Lagunes, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses an analysis looking at a practical method of determining the site of unknown primary in metastatic neuroendocrine tumors (NETs).